Back to search


Support Authera to apply for WomenTech EU

Awarded: NOK 49,999

Project Manager:

Project Number:


Project Period:

2024 - 2024



Neovascular age-related macular degeneration (nAMD) is a leading cause of vision loss, estimated to affect >50M by 2040. However, up to 40% of patients do not respond well to current treatments or develop resistance over time, driving the need for new options. To meet this need, Authera develops a therapeutic antibody targeting a new target with tailored mode-of-action. Our solution offers a new strategy to that of competitors. An already awarded IPN grant from the RCN together with SkatteFUNN partially fund the R&D activities of the first three year of our antibody development program. However, to succeed as a deep tech company, the Womentech EU grant is needed to support critical activities related to organization building, business development and establishment of an investor strategy to improve our business-readiness level. Simone Mester (CEO) and the biotechnology start-up Authera are applying to WomenTech EU as their first EU grant. As such, we are applying for PES to get support to cover our expenses related to the application process.

Funding scheme: